The worldwide emergence of drug-resistant Gram-negative rods

Japanese Journal of Chemotherapy

Volumn 59, Issue 1, 2011, Pages 8-16

  Yano, Hisakazu ^a   Hirakata, Yoichi ^a   Kaku, Mitsuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acinetobacter spp; Extended spectrum lactamases; Gram negative rod; KPC; NDM 1

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBAPENEMASE; CEPHALOSPORIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; KPC PROTEIN; MEROPENEM; METALLO BETA LACTAMASE; MONOBACTAM; NDM 1 PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; BROTH DILUTION; DRUG TREATMENT FAILURE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INDIA; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; POPULATION DYNAMICS; PUBLIC HEALTH PROBLEM;

EID: 79952204868     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Kumarasamy K K, Toleman M A, Walsh T R, Bagaria J, Butt F, Balakrishnan R, et al: Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602
2. Ambler R P: The structure of β-lactamases. Philos Trans R Soc Lond Ser B Biol Sci 1980; 289: 321-31
3. NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53: 5046-54
4. Rolain J M, Parola P, Cornaglia G: New Delhi metallo-β-lactamase (NDM-1): towards a new pandemia? Clin Microbiol Infect 2010; 16: 1699-701
5. Carattoli A: Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother 2009; 53: 2227-38
6. Yigit H, Queenan A M, Anderson G J, Domenech-Sanchez A, Biddle J W, Steward C D, et al: Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 1151-61 (Pubitemid 32230996)
7. Woodford N, Tierno P M Jr, Young K, Tysall L, Palepou M F, Ward E, et al: Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004; 48: 4793-9 (Pubitemid 39577686)
8. Nordmann P, Cuzon G, Naas T: The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228-36
9. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, et al: Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005; 49: 3018-20
10. Weisenberg S A, Morgan D J, Espinal-Witter R, Larone D H: Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis 2009; 64: 233-5
11. Tsakris A, Kristo I, Poulou A, Markou F, Ikonomidis A, Pournaras S: First occurrence of KPC-2-possessing Klebsiella pneumoniae in a Greek hospital and recommendation for detection with boronic acid disc tests. J Antimicrob Chemother 2008; 62: 1257-60
12. Clinical and Laboratory Standards Institute: M100-S20 June 2010 Update, Performance Standards for Antimicrobial Susceptibility Testing; Update (M100-S20-U). Wayne, PA. 2010
13. Bush K, Jacoby G A, Medeiros A A: A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33
14. Pitout J D, Laupland K B: Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66
15. Cantón R, Coque T M: The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006; 9: 466-75
16. Bradford P A: Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat Clin Microbiol Rev 2001; 14: 933-51
17. Yagi T, Kurokawa H, Senda K, Ichiyama S, Ito H, Ohsuka S, et al: Nosocomial spread of cephem-resistant Escherichia coli strains carrying multiple Toho-1-like β-lactamase genes. Antimicrob Agents Chemother 1997;41:2606-11 (Pubitemid 27524728)
18. Pitout J D, Nordmann P, Laupland K B, Poirel L: Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-9 (Pubitemid 41418336)
19. Peirano G, Richardson D, Nigrin J, McGeer A, Loo V, Toye B, et al: High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-β-lactamase-producing Escherichia coli isolates from Canada Antimicrob Agents Chemother 2010; 54: 1327-30
20. Tian S F, Chen B Y, Chu Y Z, Wang S: Prevalence of rectal carriage of extended-spectrum β-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol 2008; 54:781-5
21. Yu W L, Chuang Y C, Walther-Rasmussen J: Extended-spectrum β-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 2006; 39: 264-77
22. Hawkey P M, Jones A M: The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64 (Suppl 1): i3-10
23. Damjanova I, Tóth A, Pászti J, Hajbel-Vékony G, Jakab M, Berta J, et al: Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type β-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005 - the new 'MRSAs'? J Antimicrob Chemother 2008; 62: 978-85
24. Nicolas-Chanoine M H, Blanco J, Leflon-Guibout V, Demarty R, Alonso M P, Caniça M M, et al: Intercontinental emergence of Escherichia coli clone O25: H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61: 273-81
25. Peirano G, Pitout J D: Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25: H4. Int J Antimicrob Agents 2010; 35: 316-21
26. Karim A, Poirel L, Nagarajan S, Nordmann P : Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 2001; 201: 237-41
27. Pitout J D, Church D L, Gregson D B, Chow B L, McCracken M, Mulvey M R, et al: Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary health region: emergence of CTX-M-15-producing isolates. Antimicrob Agents Chemother 2007; 51: 1281-6 (Pubitemid 46586806)
28. Robicsek A, Jacoby G A, Hooper D C: The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6: 629-40
29. Strahilevitz J, Jacoby G A, Hooper D C, Robicsek A: Plasmid-mediated quinolone resistance: a multifaceted threat Clin Microbiol Rev 2009; 22: 664-89
30. Mammeri H, Van De Loo M, Poirel L, Martinez-Martinez L, Nordmann P: Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother 2005; 49: 71-6 (Pubitemid 40065774)
31. Martínez-Martínez L, Pascual A, Jacoby G A: Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797-9 (Pubitemid 28112342)
32. Saga T, Akasaka T, Takase H, Tanaka M, Sato K, Kaku M: First detection of the plasmid-mediated quinolone resistance determinant qnrA in Enterobacteriaceae clinical isolates in Japan. Int J Antimicrob Agents 2007; 29: 738-48
33. Peleg A Y, Seifert H, Paterson D L: Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-82
34. Rosenthal V D, Maki D G, Jamulitrat S, Medeiros E A, Todi S K, Gomez D Y, et al: International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control 2010; 38: 95-104
35. Choi W S, Kim S H, Jeon E G, Son M H, Yoon Y K, Kim J Y, et al: Nosocomial outbreak of carbapenem-resistant Acinetobacter baumannii in intensive care units and successful outbreak control program. J Korean Med Sci 2010; 25: 999-1004
36. Chan P C, Huang L M, Lin H C, Chang L Y, Chen M L, Lu C Y, et al: Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit Infect Control Hosp Epidemiol 2007; 28: 423-9
37. OXA-58 in Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 1442-8
38. Kohlenberg A, Brümmer S, Higgins P G, Sohr D, Piening B C, de Grahl C, et al: Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre. J Med Microbiol 2009; 58: 1499-507
39. Falagas M E, Karageorgopoulos D E: Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: Need for international harmonization in terminology. Clin Infect Dis 2008; 46: 1121-2 (Pubitemid 351589881)
40. Maragakis L L, Perl T M: Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46: 1254-63 (Pubitemid 351589912)
41. Munoz-Price L S, Weinstein R A: Acinetobacter infection. N Engl J Med 2008; 358: 1271-81
42. Higgins P G, Dammhayn C, Hackel M, Seifert H: Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233-8
43. Turner P J: MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009; 63: 217-22
44. Halstead D C, Abid J, Dowzicky M J: Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the tigecycline evaluation and surveillance trial. J Infect 2007; 55: 49-57 (Pubitemid 46900073)
45. Mendes R E, Bell J M, Turnidge J D, Castanheira M, Jones R N: Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother 2009; 63: 55-9
46. Brink A, Moolman J, da Silva M C, Botha M: National Antibiotic Surveillance Forum: Antimicrobial susceptibility profile of selected bacteraemic pathogens from private institutions in South Africa. S Afr Med J 2007; 97: 273-9 (Pubitemid 46614306)
47. Kallen A J, Hidron A I, Patel J, Srinivasan A: Multidrug resistance among Gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 2010; 31: 528-31
48. Higgins P G, Dammhayn C, Hackel M, Seifert H: Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233-8
49. Nemec A, Krizová L, Maixnerová M, Diancourt L, van der Reijden T J, Brisse S, et al: Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II. J Antimicrob Chemother 2008; 62: 484-9
50. Endo S, Yano H, Hirakata Y, Arai K, Kanamori H, Ogawa M, et al: First surveillance report from Japan: Molecular and carbapenem resistance epidemiology of Acinetobacter spp. Antimicrob Agents Chemother. (in submission)